Multiple myeloma is a type of cancer formed by malignant plasma cells that usually arises in the bone marrow. The disease occurs mostly with people over the age of 50. It comprises about 1% of all cancers and 10% of all blood and bone marrow cancers. Each year about 200 people in NZ are diagnosed with multiple myeloma. Common symptoms of multiple myeloma are: bone pain, anaemia, frequent or repeated infections and increased bleeding or bruising.

Thalidomide is indicated for the treatment of refractory or relapsed multiple myeloma. Thalidomide is only available for patients when they participate in a risk management programme that ensures all measures are taken to avoid pregnancies whilst taking the drug. The Pharmion Risk Management Programme (PRMP) is a comprehensive system that involves the patient, prescriber and pharmacist.
 

Consumer Medicines Information

Click here to view the CMI data sheet